Review article · 2026 · Open access

cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges

Xiangliang Lin, Thi Van Anh Bui

Cytotherapy, 28(10), 102815 · Published 4 April 2026 · DOI 10.1016/j.jcyt.2026.102815

Open full textCite this paper

In brief

“cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges” is a 2026 review article by Xiangliang Lin and Thi Van Anh Bui, published in Cytotherapy. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Cytotherapy.

Citations
0
References
143
Authors
2

Abstract

Induced pluripotent stem cells (iPSCs), which can be applied to disease modeling, regenerative medicine, and cultivated meat, among other uses, have opened a new era in the biomedical field. To obtain sufficient high-quality cells for these applications, a current good manufacturing practice (cGMP)-compliant large-scale expansion is necessary. It indicates that the entire process for producing iPSCs should adhere to cGMP regulations, encompassing both upstream steps, such as raw material collection, reprogramming, and large-scale expansion, as well as downstream steps, including harvesting, concentrating, and cryopreserving the cells. Importantly, well-established critical quality attributes are mandatory to ensure the quality of the produced cells. For decades, huge efforts have been made to initiate and develop each step of the process. However, there are still limitations and obstacles that slow down the progress of the cGMP large-scale production of iPSC. Therefore, in this review, we summarize the accomplishments and challenges of current technologies involved in making applicable and clinical iPSCs. Throughout this, future directions and solutions can be suggested for the production of large-scale, high-quality iPSCs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Lin, X., & Bui, T. V. A. (2026). cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges. Cytotherapy, 28(10), 102815. https://doi.org/10.1016/j.jcyt.2026.102815

MLA 9

Lin, Xiangliang, and Thi Van Anh Bui. “cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges.” Cytotherapy, vol. 28, no. 10, 2026, p. 102815. https://doi.org/10.1016/j.jcyt.2026.102815.

Chicago

Lin, Xiangliang and Thi Van Anh Bui. 2026. “cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges.” Cytotherapy 28 (10): 102815. https://doi.org/10.1016/j.jcyt.2026.102815.

Harvard

Lin, X. and Bui, T. V. A. (2026) ‘cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges’, Cytotherapy, 28(10), p. 102815. doi:10.1016/j.jcyt.2026.102815.

IEEE

X. Lin and T. V. A. Bui, “cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges,” Cytotherapy, vol. 28, no. 10, p. 102815, 2026, doi: 10.1016/j.jcyt.2026.102815.

BibTeX

@article{lin2026cgmp,
  title     = {{cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges}},
  author    = {Lin, Xiangliang and Bui, Thi Van Anh},
  journal   = {Cytotherapy},
  year      = {2026},
  volume    = {28},
  number    = {10},
  pages     = {102815},
  doi       = {10.1016/j.jcyt.2026.102815},
  url       = {https://doi.org/10.1016/j.jcyt.2026.102815}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • induced pluripotent stem cells
  • cyclic GMP
  • large-scale cell expansion
  • critical quality attributes
  • cellular reprogramming
  • cell cryopreservation
  • cell harvesting
  • disease modeling

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Lin, X., & Bui, T. V. A. (2026). cGMP-compliant large-scale manufacturing of human-induced pluripotent stem cells: current progress and challenges. Cytotherapy, 28(10), 102815. https://doi.org/10.1016/j.jcyt.2026.102815

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cytotherapy: sign in and open the full text from this page.

Who wrote this paper?

Xiangliang Lin, Thi Van Anh Bui.

What is the DOI of this paper?

10.1016/j.jcyt.2026.102815, permanently at https://doi.org/10.1016/j.jcyt.2026.102815. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.